Patents by Inventor Shweta Singh

Shweta Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD166 ANTIBODIES, ACTIVATABLE ANTI-CD166 ANTIBODIES, AND METHODS OF USE THEREOF
    Publication number: 20200291113
    Abstract: The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: December 20, 2019
    Publication date: September 17, 2020
    Inventors: James William WEST, Jason Gary Sagert, Jonathan Alexander Terrett, Annie Yang Weaver, Luc Roland Desnoyers, Shweta Singh
  • Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
    Patent number: 10745481
    Abstract: The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: August 18, 2020
    Assignee: CytomX Therapeutics, Inc.
    Inventors: James William West, Jason Gary Sagert, Jonathan Alexander Terrett, Annie Yang Weaver, Luc Roland Desnoyers, Shweta Singh
  • ANTI-CD38 BINDING DOMAINS
    Publication number: 20200231696
    Abstract: Provided in this disclosure are anti-CD38 binding domains, a composition comprising the anti-CD38 binding domains, nucleic acids encoding the anti-CD38 binding domains, and a method of using the anti-CD38 binding domains or the composition for treating multiple myeloma.
    Type: Application
    Filed: January 23, 2020
    Publication date: July 23, 2020
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Vinay Bhaskar, Erin Willert
  • Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
    Patent number: 10577420
    Abstract: The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: March 3, 2020
    Assignee: CytomX Therapeutics, Inc.
    Inventors: James William West, Jason Gary Sagert, Jonathan Alexander Terrett, Annie Yang Weaver, Luc Roland Desnoyers, Shweta Singh
  • ANTI-CD38 ANTIBODIES
    Publication number: 20200040105
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Application
    Filed: October 17, 2019
    Publication date: February 6, 2020
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • CONJUGATED ANTI-CD38 ANTIBODIES
    Publication number: 20200031951
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Application
    Filed: May 14, 2019
    Publication date: January 30, 2020
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • C10RF32 ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER
    Publication number: 20200002416
    Abstract: This invention relates to C1ORF32-specific antibodies, antibody fragments, alternative scaffolds, conjugates and compositions comprising same, for treatment of cancer.
    Type: Application
    Filed: May 14, 2019
    Publication date: January 2, 2020
    Inventors: Gady S. COJOCARU, Galit ROTMAN, Zurit LEVINE, Liat DASSA, Ofer LEVI, Raffaella BRIANTE, Shweta SINGH, Susan R. WATSON, Tania PERGAM
  • Anti-CD38 antibodies
    Patent number: 10494444
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: December 3, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • ANTI-ITGA3 ANTIBODIES, ACTIVATABLE ANTI-ITGA3 ANTIBODIES, AND METHODS OF USE THEREOF
    Publication number: 20190309072
    Abstract: The invention relates generally to antibodies that bind ITGa3, activatable antibodies that specifically bind to ITGa3 and methods of making and using these anti-ITGa3 antibodies and anti-ITGa3 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: January 18, 2019
    Publication date: October 10, 2019
    Inventors: Jason Gary SAGERT, Jonathan Alexander Terrett, Luc Roland Desnoyers, Shweta Singh, Annie Yang Weaver
  • ANTI-CD71 ANTIBODIES, ACTIVATABLE ANTI-CD71 ANTIBODIES, AND METHODS OF USE THEREOF
    Publication number: 20190202927
    Abstract: The invention relates generally to antibodies that bind CD71, activatable antibodies that specifically bind to CD71 and methods of making and using these anti-CD71 antibodies and anti-CD71 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: November 13, 2018
    Publication date: July 4, 2019
    Inventors: Jason Gary Sagert, Kimberly Ann Tipton, Jonathan Alexander Terrett, Shweta Singh, Annie Yang Weaver, Luc Roland Desnoyers
  • Conjugated anti-CD38 antibodies
    Patent number: 10336833
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: July 2, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • ANTI-CD71 ACTIVATABLE ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF
    Publication number: 20190111150
    Abstract: The invention relates generally to conjugated activatable antibodies that bind CD71 in their active form and methods of making and using these anti-CD71 conjugated activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: October 12, 2018
    Publication date: April 18, 2019
    Inventors: Shweta SINGH, Jennifer Hope RICHARDSON, Laura Patterson SERWER, Jonathan Alexander TERRETT, Susan E. MORGAN-LAPPE, Tracy HENRIQUES, Sherry L. RALSTON, Marvin Robert LEANNA, Ilaria BADAGNANI, Sahana BOSE
  • Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof
    Patent number: 10233244
    Abstract: The invention relates generally to antibodies that bind ITGa3, activatable antibodies that specifically bind to ITGa3 and methods of making and using these anti-ITGa3 antibodies and anti-ITGa3 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: March 19, 2019
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Jason Gary Sagert, Jonathan Alexander Terrett, Luc Roland Desnoyers, Shweta Singh, Annie Yang Weaver
  • Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof
    Patent number: 10179817
    Abstract: The invention relates generally to antibodies that bind CD71, activatable antibodies that specifically bind to CD71 and methods of making and using these anti-CD71 antibodies and anti-CD71 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: January 15, 2019
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Jason Gary Sagert, Kimberly Ann Tipton, Jonathan Alexander Terrett, Shweta Singh, Annie Yang Weaver, Luc Roland Desnoyers
  • LIPIDS AS SYNTHETIC VECTORS TO ENHANCE ANTIGEN PROCESSING AND PRESENTATION EX-VIVO IN DENDRITIC CELL THERAPY
    Publication number: 20180353599
    Abstract: The invention covers the use of certain classes of lipids including cationic lipids in ex-vivo dendritic cell therapies. The cationic lipids enhance antigen uptake, processing and presentation of the processed antigens by dendritic cells to CD8+ and CD4+ T-cells via the MHC classes I and II presentation pathways respectively. Antigen uptake via cationic lipid by dendritic cells result in significant lowering of the population of the immune suppressive regulatory T cells in the tumors and a significant increase of the tumor targeting cytotoxic T-cells. Loss of regulatory T cells and increase of tumor specific cytotoxic cells are conducive to effective elimination of the tumors.
    Type: Application
    Filed: November 14, 2016
    Publication date: December 13, 2018
    Inventors: Frank Bedu-Addo, Greg Conn, Siva K. Gandhapudi, Martin Keough, Angela Mohs, Ritu Patel, Shweta Singh, Martin Ward, Jerold Woodward
  • ANTI-CD38 ANTIBODIES
    Publication number: 20180066069
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Application
    Filed: September 13, 2017
    Publication date: March 8, 2018
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • CONJUGATED ANTI-CD38 ANTIBODIES
    Publication number: 20180016349
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Application
    Filed: May 17, 2017
    Publication date: January 18, 2018
    Inventors: Kathleen Ann ELIAS, Gregory LANDES, Shweta SINGH, Wouter KORVER, Andrew Walling DRAKE, Mary HAAK-FRENDSCHO, Gyorgy Pal SNELL, Vinay BHASKAR
  • Anti-CD38 antibodies
    Patent number: 9790285
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: October 17, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • C10RF32 ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER
    Publication number: 20170233473
    Abstract: This invention relates to C1ORF32-specific antibodies, antibody fragments, alternative scaffolds, conjugates and compositions comprising same, for treatment of cancer.
    Type: Application
    Filed: February 28, 2017
    Publication date: August 17, 2017
    Applicant: Compugen Ltd.
    Inventors: Gady S. COJOCARU, Galit ROTMAN, Zurit LEVINE, Liat DASSA, Ofer LEVI, Raffaella BRIANTE, Shweta SINGH, Susan R. WATSON, Tania PERGAM
  • Conjugated anti-CD38 antibodies
    Patent number: 9676869
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: June 13, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar